Targeting DNA Ligase III Addiction in T-Cell Acute Lymphoblastic Leukemia by the Natural Flavonoid Rhamnetin

T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy with dismal outcomes in relapsed/refractory settings, where nelarabine remains the sole approved agent with limited frontline efficacy. Genomic instability in T-ALL is sustained by a rewired DNA repair network, yet the functional reliance on DNA Ligase III (LIG3)-dependent alternative non-homologous end joining remains largely unexplored. By interrogating public transcriptomic cohorts, functional DepMap datasets, and siRNA-mediated knockdown, we evaluated LIG3 expression and essentiality in T-ALL. Pharmacological targeting was evaluated using Rhamnetin (RHM), a previously characterized LIG3-binding flavonoid, alone or combined with nelarabine across T-ALL cell lines and healthy peripheral blood mononuclear cells. LIG3 mRNA was uniformly expressed across T-ALL oncogenic subgroups. Functional assays confirmed LIG3 essentiality in T-ALL models. RHM dose-dependently reduced viability and clonogenic potential while sparing healthy cells. Mechanistically, RHM triggered a canonical DNA damage response with CHK1/CHK2 phosphorylation and γH2AX accumulation, driving CDC25A down-regulation, cell cycle perturbation, and apoptosis. Furthermore, RHM enhanced the anti-leukemic efficacy of nelarabine, displaying synergistic to additive interactions. These findings suggest LIG3 as an actionable dependency in T-ALL cells and support LIG3 inhibition, alone or combined with nelarabine, for therapeutic development.

Authors

Institutions

Publication Details

Journal
International Journal of Molecular Sciences
Published
2026-11-12
DOI
https://doi.org/10.3390/ijms272210148
Primary Topic
Acute Lymphoblastic Leukemia research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Targeting DNA Ligase III Addiction in T-Cell Acute Lymphoblastic Leukemia by the Natural Flavonoid Rhamnetin

Pierosandro Tagliaferri, Emanuela Altomare, Katia Grillone, Licia Pensabene et al.
International Journal of Molecular Sciences
Acute Lymphoblastic Leukemia research
article

Targeting DNA Ligase III Addiction in T-Cell Acute Lymphoblastic Leukemia by the Natural Flavonoid Rhamnetin

Pierosandro Tagliaferri, Emanuela Altomare, Katia Grillone, Licia Pensabene, Serena Ascrizzi, Stefania Signorelli, Pierfrancesco Tassone, Nicoletta Polerà, Giada Juli, Daniele Caracciolo, Sara Squillacioti, Maria Gaetano, Amalia Gagliardi
article en

Abstract

T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy with dismal outcomes in relapsed/refractory settings, where nelarabine remains the sole approved agent with limited frontline efficacy. Genomic instability in T-ALL is sustained by a rewired DNA repair network, yet the functional reliance on DNA Ligase III (LIG3)-dependent alternative non-homologous end joining remains largely unexplored. By interrogating public transcriptomic cohorts, functional DepMap datasets, and siRNA-mediated knockdown, we evaluated LIG3 expression and essentiality in T-ALL. Pharmacological targeting was evaluated using Rhamnetin (RHM), a previously characterized LIG3-binding flavonoid, alone or combined with nelarabine across T-ALL cell lines and healthy peripheral blood mononuclear cells. LIG3 mRNA was uniformly expressed across T-ALL oncogenic subgroups. Functional assays confirmed LIG3 essentiality in T-ALL models. RHM dose-dependently reduced viability and clonogenic potential while sparing healthy cells. Mechanistically, RHM triggered a canonical DNA damage response with CHK1/CHK2 phosphorylation and γH2AX accumulation, driving CDC25A down-regulation, cell cycle perturbation, and apoptosis. Furthermore, RHM enhanced the anti-leukemic efficacy of nelarabine, displaying synergistic to additive interactions. These findings suggest LIG3 as an actionable dependency in T-ALL cells and support LIG3 inhibition, alone or combined with nelarabine, for therapeutic development.

International Journal of Molecular SciencesVol. 27(22)
Magna Graecia University (IT), Institute for Biomedical Research and Innovation (IT), National Research Council (IT)
Good health and well-being
Acute Lymphoblastic Leukemia research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon